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BACKGROUND: The ingestion of wheat and other cereals are related to several gut 
disorders. The specific components responsible for NCWS may include gluten and other 
compounds. Tritordeum is a new cereal derived from crossing durum wheat with a wild barley 
species, which differs from bread wheat in its gluten composition. In the present work, we 
examined the response of NCWS patients to tritordeum bread Gastrointestinal symptoms as 
well as tritordeum acceptability, Gluten Immunogenic Peptides excretion, and the composition 
and structure of the intestinal microbiota were evaluated.  
RESULTS: Gastrointestinal symptoms of the subjects showed no significant change 
between the gluten-free bread and the tritordeum bread. Participating subjects rated 
tritordeum bread higher than the gluten-free bread. Analysis of the bacterial gut microbiota 
indicated that tritordeum consumption does not alter the global structure and composition of 
the intestinal microbiota, and only a few changes in some butyrate-producing bacteria were 
observed. 
CONCLUSIONS: All the results derived from acceptability, biochemical and 
microbiological tests suggest that tritordeum may be tolerated by a sub-set of NCWS sufferers 
who do not require strict exclusion of gluten from their diet.  
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The cereals, and in particular wheat, have a central role in human diet and are 
important sources of complex carbohydrate, protein and dietary fiber as well as minerals, 
vitamins and phyto-active compounds (1). They have highly valued organoleptic properties and 
are functionally versatile allowing them to be use in a great number of food applications. 
Although in general the cereals are very safe foodstuffs consumed routinely by billions of 
people, they are implicated in some food allergies and dietary intolerances, mainly related to 
their protein composition and in particular to gluten proteins present in cereals such as wheat, 
barley and rye. Gluten-related disorders include wheat allergy (WA) an allergic reaction 
associated with a spectrum of different proteins, including gliadins and amylase trypsin 
inhibitors (ATIs) (2); celiac disease (CD), an immune-mediated enteropathy induced by 
exposure to dietary gluten and non-celiac gluten sensitivity (NCWS) a disease related to the 
ingestion of gluten-containing foods in persons who do not suffer from WA or CD (3, 4). The 
specific components responsible for NCWS have still to be confirmed and may include gluten 
proteins, ATIs, fermentable mono- and polysaccharides and polyols (FODMAPS) or other 
factors (4), but with an estimated frequency of 6 – 13% the number of persons affected by 
NCWS is significantly higher than WA (around 1-2%) or CD (around 1%) (3-6).  Although there is 
evidence that not all NCWS sufferers need to exclude gluten completely from their diet as they 
may have different levels of tolerance (7), many follow a gluten-free diet (GFD), although this 
may have negative nutritional implications as GFDs containing more fat and less carbohydrate 
than recommended and tend to be poorer in several important dietary components  such as 
folic acid, calcium, iron and vitamin B6, B12 and D (8, 9). In addition a strict GFD may have 
negative effects on gut microbiota (10-12). In fact, a microbial dysbiosis in NCWS causes gut 
inflammation, abdominal pain, metabolic problems, neuroinflammation, gut-brain axis 
dysfunction, intestinal barrier defects and inflammatory responses to gluten, among others 
(13, 14). In addition, Uhde et al. (15) demonstrated the existence of an increased intestinal 
 
 
permeability in subjects with non-celiac/non-allergic gluten/wheat sensitivity (NCG/WS). 
Although changes in intestinal microbiota had been associated to gluten free diet (16), those 
may also exist in NCWS patients but this has not been proven yet (17). It is known that 
bacterial species mainly belonging to Firmicutes phylum, perform important immunological, 
structural and metabolic functions in the host, among which, it should be noted its 
involvement in the preservation of the integrity of the intestinal barrier through the 
production of short-chain fatty acids (SCFA) (18), so that increased intestinal permeability in 
subjects with NCG/WS described by Uhde et al. (15) could indicate a possible key pathogenic 
role of the intestinal microbiota in these patients. 
In this context, it is of interest to explore whether NCWS sufferers may safely consume 
cereal foods modified by techniques such as sourdough fermentation which can reduce levels 
of gluten proteins and FODMAPS (19, 20) or made using alternative gluten sources which may 
be better tolerated as they have lower levels of symptom-inducing components (21). In a 
previous study, the present authors showed that tritordeum, a new cereal crop species derived 
from crossing durum wheat with a wild barley species (22, 23) differs from bread wheat in its 
gluten composition, in particular with respect to gliadin composition, showing significantly 
lower levels of gluten immunogenic peptides (GIP) implicated in CD and possibly also in NCWS. 
In addition, it was seen that healthy subjects who consumed a tritordeum diet during one 
week showed a significant reduction of the excretion of GIP in feces by comparison with a 
bread wheat diet (21). The present study follows on from the previous work, with the aim of 
examining the response of patients diagnosed as NCWS to tritordeum breads, to test the 
hypothesis that the reduced GIP levels in tritordeum may allow some NCWS patients to 
tolerate it in their diet. Additionally, the study analyses the effect of its consumption on the 
intestinal microbiota of these patients, due to the recent idea, that changes in the intestinal 
microbiota composition could contribute to the etiology and pathogenesis of NCWS (13). 
 
 
MATERIALS AND METHODS 
Subjects 
The study population was obtained from a gastroenterology outpatient clinic at the 
University Hospital of León specialized in gluten-related disorders mainly celiac disease and 
NCWS.   Patients suffering NCWS were selected from our database with the following inclusion 
criteria:  (i) fulfill the Salerno criteria for NCWS diagnosis (24), (ii) diagnosed at least 6 months 
previously to the study, (iii) following a strict gluten-free diet with complete symptom 
remission, (iv) not suffer from any other chronic disease or taking long-term medication.  A 
total of 30 patients were contacted, 12 did not fulfill inclusion criteria and 6 refuse to 
participate in the study (Fig. 1).  Finally, the subjects for the diet intervention were twelve 
adult volunteers (9 / 12 female) of age 31-57 years.  All of them showed negative serology for 
celiac disease (tissue-transglutaminase IgA antibodies) and the duodenal biopsy results 
presented normal duodenal villi architecture. HLA-DQ2+ was present in five of the subjects, 
whilst the remaining seven showed a different HLA-DQ2 or DQ8 haplotype. Of the twelve 
subjects who started the study, two withdrew voluntarily during the first days of the diet 
intervention (during the Basal, GFD phase), as they were not able to attend to deliver stool 
samples (the two were female with HLA-DQ2 or DQ8 not present). Their withdrawal was not 
associated with any change in gastro-intestinal symptoms or any other physiological reason. 
The remaining ten subjects followed the two phases of the study, completed the clinical and 
sensory questionnaires and provided the required stool samples.  They were instructed to 
communicate any medication needed to take during the study period.  All study participants 
provided informed consent, and the study design was approved by the Ethics Review Board of 






The study was performed in two phases (“Basal” and “Tritordeum”), each of which had 
duration of seven days. At the beginning of the study, subjects were given a hand-out 
explaining the background / objectives of the diet intervention and giving instructions for the 
handling and consumption of the bread samples and the collection and delivery of stool 
samples. 
Basal phase: consumption of the GFD normally eaten by the subject including the 
consumption of the gluten-free bread habitually consumed by each individual.  They were 
instructed to eat an amount of their gluten-free bread between 100-150 g daily.  At the end of 
the phase, Clinical Questionnaires based on Gastrointestinal Symptom Rating Scale (GSRS) and 
Sensory Questionnaires (Table S1) on palatability and acceptability of the bread consumed (21) 
were completed and stool samples (Basal phase samples) were collected. 
Tritordeum phase: Continuation of the Basal GFD, but with the substitution of the 
Basal (gluten-free) bread by tritordeum bread during seven days. Subjects were instructed to 
consume a minimum of 100 g and a maximum of 150 g of tritordeum bread daily, by the 
consumption of four slices of bread, giving a daily intake of ca. 5 - 7.5 g of gluten, based on the 
gluten content of the same tritordeum breads previously reported (21). At the end of this 
phase, the Clinical and Sensory Questionnaires were completed and stool samples (Tritordeum 
phase samples) were collected. 
 
Preparation and provision of test breads 
  The ingredients for the tritordeum breads provided to subjects in the 
Tritordeum phase were: flour, water, sourdough, salt, and baker’s yeast. Breads were made 
using tritordeum sourdough, prepared 24 h before bread-making, by mixing tritordeum flour, 
 
 
water and sourdough starter culture (composed of flour, water, lactic acid bacteria and 
sourdough yeasts). The mixture was allowed to stand at room temperature for 3 h before 
storage at 5 ºC until use. For bread-making, the main dough got 150g Kg of tritordeum 
sourdough, and mixed with additional tritordeum flour, water, salt and baker yeast to form the 
final dough. This dough rested for 90 min at room temperature (22-24ºC). After resting bulk 
dough was divided into pieces, which were placed into metal loaf molds and allowed to 
ferment until they achieved 2/3 of the mold volume (approximately 90 min). Loaves were 
baked at 210 ºC - for 45 min. The acidity values of the tritordeum sourdough and tritordeum 
bread are the following; Tritordeum Sourdough: TTA 13, pH 4.05, Tritordeum Bread: pH 4.9  
 After cooling, loaves were cut into slices and frozen in portions. The bread was 
stored at the Hospital of León, where the subjects received the bread for the Tritordeum 
phase. The breads were supplied frozen to test subjects for defrosting immediately before 
consumption. 
 
Evaluation of gastrointestinal symptoms 
Gastrointestinal symptoms were reported by participating subjects using the GSRS 
questionnaire, a validated, self-administered questionnaire that includes 15 questions, which 
assess gastrointestinal symptoms using a 7-point Likert scale in five domains: Indigestion, 
Diarrhea, Constipation, Abdominal Pain and Reflux. The severity of symptoms reported in the 
GSRS increases with increasing score. 
 
Evaluation of acceptability of breads 
The Sensory Questionnaire required the subjects to score the bread consumed during 
the Basal and Tritordeum phases under five attributes: Appearance; Aroma; Crumb Texture; 
 
 
Taste; and Overall Acceptability, using a numerical scale of 1 – 9, each number corresponding 
to a description of the level of liking / dislike of the bread. 
 
Collection of stool samples 
Subjects were instructed to collect a 2-4 g stool sample into a sealed container after 
recording their food intake for seven days. Specimens were delivered within the first two 
hours after deposition and were stored at -80 ºC until processing. All samples were identified 
and labelled with a randomized numeric code. 
 
Quantification of GIP in stool samples 
In the study a total of 20 stool samples were analyzed from 10 subjects. The 
concentration of GIP in stools was measured by sandwich ELISA (iVYDAL In Vitro Diagnostics® 
iVYLISA GIP-S kit, Biomedal S.L., Seville, Spain) following the manufacturer’s guidelines (21). 
Briefly, stool samples were mixed with 9 ml Universal Gluten Extraction Solution (UGES) per 
gram of stool then incubated at 50ºC for 60 min with gentle agitation to release the GIP from 
the stool matrix. After extraction, samples were diluted 1:10 with dilution solution and ELISA 
was performed using the provided G12 coated microtiter plate, standards and positive and 
negative controls. Each sample was run in duplicate and at least two different aliquots of each 
sample were tested on different days.  
 
Sequencing and Bioinformatics Analysis of the gut microbiota 
For each DNA of 36 fecal samples (9 patients per two phase of study and two DNA 
repetitions for each phase), the V1-V2 hypervariable regions of the bacterial 16S rRNA gene 
was amplified by polymerase chain reaction (PCR) using the universal bacterial primers 8F 
 
 
(AGAGTTTGATCMTGGCTCAG) and 357R (CTGCTGCCTYCCGTA). In addition, 8nt index and 
Illumina adapter sequences were added following manufacturer’s instructions. The PCR 
experimental conditions and single-end sequencing procedures were the same as in a previous 
study (25). The raw NGS data from this study can be found at GenBank database under 
accession number PRJNA577543. 
The Illumina Miseq Fastq reads obtained were analyzed using the Quantitative Insights 
into Microbial Ecology 2 (QIIME 2) pipeline (version v2019.7) (26) with default parameters 
unless otherwise noted. Reads were processed by the DADA2 program using the qiime dada2 
denoise-single script (27) which denoises single-end sequences, dereplicates them, and filters 
chimeras. Open reference operational taxonomic unit (OTU) picking was performed using 
VSEARCH (28) and the  SILVA v132 reference databases at 97% identity, which provides a 
feature table containing the frequencies of each OTU or taxon per sample (29).  
Rarefaction curves of alpha-diversity indexes (Faith_pd, Shannon, Observed OTUS and 
Good’s coverage) and beta diversity (Unweighted and Weighted UniFrac distances) were 
calculated at an even sampling depth of 10,044 sequences per sample and used to assess 
differences in microbial diversity between the two phases of the study 
(https://github.com/qiime2/q2-diversity). Finally, taxonomic and compositional analyses were 




Megazyme Fructan HK enzymatic assay kit (Megazyme, Bray, Ireland) was used for the 




Protein peptides analysis by Liquid Chromatography–Tandem Mass Spectrometry Analysis  
Total protein extraction and trypsin and chymotrypsin digestion of samples were 
carried out from 2 g of flour as previously reported (21). 
 
Statistical analysis 
The ANOVA test was performed to evaluate differences between various samples, 
followed by the two-tailed Dunnett’s post hoc test for multiple mean comparisons. The 
Student’s t test, Wilcoxon test and Friendman test were employed to analyze differences in 
the same subject among the different phases. The Bonferroni test was applied in the post hoc 
analysis and P-values lower than 0.05 were considered statistically significant. 
A non-supervised multivariate hierarchical clustering analysis, using Euclidean distance 
and the Ward clustering algorithm, and a supervised principal least square-discriminant 
analysis (PLS-DA) of all bacterial taxa from the different periods of dietary intervention were 
performed using MetaboAnalyst 4.01 (31). 
Differences in alpha diversity indexes were estimated using the non-parametric Kruskal 
Wallis test and differences for the beta diversity unweighted and weighted UNIFRAC distances 
were estimated using the PERMANOVA analysis. Finally, the differences in the relative 
abundance of bacterial taxa between the two phases were tested using the non-parametric 
Mann-Whitney U test with SPSS Statistics for Windows Version 25.0 (IBM Corp., Armonk, NY). 







Tritordeum is a new cereal species obtained from crossing durum wheat with a wild barley 
species (22, 23). It is lacking the D genome and therefore, do not contain the gliadin-related 
proteins located on it, particularly the α-gliadins harbouring the 33-mer protein fragment (32, 
33), the most immunogenic peptide known so far. In previous work, we showed that 
tritordeum contain lower CD immunogenic peptides than that of bread wheat (21), particularly 
the α-gliadin peptides. As other grain proteins are related to wheat allergies and NCWS, we 
have extended the search to other grain components (Supplementary Fig. S1). As showed, ATIs 
protein peptides are slightly lower in tritordeum in comparison to that of bread wheat. 
However, other peptides, also belonging to the non-gluten proteins fraction are higher in 
tritordeum. Fructans content, an oligosaccharide of the FODMAPs, were lower in tritordeum, 
although not significantly different to that of bread wheat flour (Supplementary Fig. S1). In the 
present work we carried out a dietary intervention in NCWS patients of tritordeum breads in 
comparison with the gluten free breads they usually consumed.  
 
Participants recruitment and dietary intervention flow 
Of 30 participants recruited from the gastroenterology outpatient clinic at the University 
Hospital of León, 12 were eligible while 12 do not meet the inclusion criteria and 6 refused to 
participate (Fig. 1, see material and methods for more details). Finally, two subjects withdrew 
voluntarily during the first days of the dietary intervention (during the Basal phase) and 
excluded for the final analysis. The dietary intervention had two phases; Basal and Tritordeum, 
with a duration of seven days each (Fig. 1). All participants were following a gluten free diet 
and the only different between the two phases was the bread consumed. Participants were 
instructed to eat between 100 and 150 grams of the gluten free bread o tritordeum bread 
 
 
during the Basal or tritordeum phases, respectively. And the end of each phase, GSRS and 
Sensory questionnaires were completed and stool samples collected. 
 
Gastro-intestinal symptoms 
The results from the completion of the GSRS questionnaires, evaluating the 
parameters Indigestion, Diarrhea, Constipation, Abdominal Pain and Reflux, at the end of the 
Basal and Tritordeum phases indicated that the gastrointestinal symptoms of the subjects 
showed no significant change between the Basal phase (gluten free bread) and the Tritordeum 
phase (Fig. 2). The global mean value (data for all subjects) during the Basal phase was 36.5 vs 
34.1 during the Tritordeum phase (with higher values equating to lower gastrointestinal 
wellbeing) but these scores were not significantly different (P = 0.414). Examination of the 
questionnaire results for individual subjects showed that at the individual level there were no 
significant differences in gastrointestinal health scores (Fig. 2). 
The analysis of GIP in stool samples showed that, as expected, there was a low 
excretion of GIP (mean value 0.6 (0 – 2.9) µg GIP/g feces) by subjects during the Basal phase, 
although two subjects showed excretion levels above expected possibly due to dietary 
transgressions (Fig. 3). Higher levels of GIPs were detected in stool samples from the 
Tritordeum phase, confirming their consumption of gluten. The mean level of GIP detected in 
stool samples in the Tritordeum phase, was 1.5 µg GIP/g feces, with concentration ranged 
from 0.5 to 3.2, although this difference was not statistically significant (P = 0.114). The results 
obtained in the Tritordeum phase contrasted with those reported previously for subjects who 
included standard wheat breads containing gluten in their diet, GIP concentration ranged from  





Based on the Sensory Questionnaire, participating subjects rated tritordeum bread 
higher than the Basal (gluten-free) bread they habitually consumed for each of the five 
attributes scored (Appearance, Aroma, Texture, Taste and Overall Acceptability) and with a 
significant difference (P = < 0.05) seen with each attribute (Fig. 4). In particular, Texture and 
Taste were scored highly in tritordeum breads in comparison with gluten-free breads 
(Tritordeum mean 7.3 vs Basal mean 3.6 and Tritordeum mean 7.7 vs Basal mean 4.6, 
respectively). The mean Overall Acceptability score for tritordeum bread was 7.2 vs 5.1 for 
Basal breads (Fig. 4). 
 
Diversity and Changes of the gut microbiota  
After processing of reads a total of 361,584 sequences were retained and a sample was 
lost. The sampling depth selected for rarefication was 10,044. Satisfactory Good´s coverage of 
the diversity was obtained for all samples since the mean value was > 99.9% for al samples. We 
did not find any significant differences in bacterial diversity between the Basal phase and the 
Tritordeum phase, with any of the alpha diversity indexes used (Faith_pd, P = 0.480; Shannon, 
P = 0.635, and observed OTUS, P = 0.701) at any of the rarefaction depths analyzed (Fig. 5A). In 
the same way, we did not find any significant differences in the beta diversity between both 
phases both for Unweighted (P = 0.429) and Weighted (P = 0.461) Unifrac distances. Similarly, 
no significant differences in both Unweighted and Weighted Unifrac distances were found 
between both phases for each patient when analyzed independently (P > 0.091; Fig. 5B). 
In total, 3 phyla, 5 classes, 5 orders, 9 families and 17 genera, were identified with a 
mean relative abundance equal to or greater than 0.1% in both phases and with a presence 
equal to or greater than 65% in all samples for each phase (Supplementary Fig. S2).  
 
 
We did not find significant (P > 0.05) differences in the relative abundance of any taxa 
at phylum, class, order and family level between Basal and Tritordeum phases. On average, the 
taxa with the highest abundance both at the Basal phase and the Tritordeum phase were: 
Firmicutes 89.2% - 90.1% and Actinobacteria 3.7% - 3.2% at the phylum level, Clostridia 69.9% - 
72.2%, and Erysipelotridia 12.1% - 10.7% at class level, and Clostridiales 69.9% - 72.2% and 
Eryselotrichales 12.1% - 10.7% at order level and Lachnospiraceae 36.3% - 38.7% and 
Ruminococcaceae 26.1% - 23.9% at family level (Supplementary Fig. S2). 
Finally, at genus level we found significant differences in the relative abundance of two 
bacterial genera: a higher relative abundance in Ruminococcaceae UCG-013 (P = 0.024) and a 
lower relative abundance in Faecalibacterium (P = 0.011) genera in Basal phase as compared 
with Tritordeum phase (Fig. 7). These results are in agreement with those observed in the PLS-
DA analysis (Fig. 6). 
The hierarchical clustering analysis showed a trend to group the two dietary phases of 
each patient in pairs, indicating the maintenance of the structure and composition of the 
intestinal microbiota of each patient after consumption with tritordeum (Supplementary Fig. 
S3 and S4). PLS-DA of all bacterial taxa showed a good separation of both dietary phases (P < 
0.01; Fig. 6A) and ranked 15 bacterial taxa as the most important in projection (VIP scores > 1.5 
at P < 0.05; Fig. 6B) allowing differentiation of both phases, of which eight taxa are SCFA-
producing bacteria.  
 
DISCUSSION 
The study presented here follows a previous study on acceptance, digestibility and 
immunotoxicity of tritordeum, which showed that, in comparison with bread wheat, 
tritordeum breads were well accepted, had less gluten (49% reduction), lower levels of 
 
 
immunogenic gliadin epitopes (59% reduction in γ-gliadin epitopes, 77% reduction in α-gliadin 
epitopes) and that the levels of GIP excreted in stool samples of healthy volunteers were 
significantly reduced (21). Regarding non gluten proteins and other compounds also related 
with NCWS, tritordeum flour showed slightly lower content of ATIs protein peptides and 
comparable content of total fructans than that of bread wheat. The present work extends the 
previous study by examining the tolerance (gastro-intestinal health) and acceptance of 
tritordeum breads by patients diagnosed with NCWS who habitually follow a GFD. The impact 
of tritordeum consumption on the gut microbiota of these patients was also evaluated.  
Considering the tolerance of tritordeum breads by participating subjects, the analysis 
of GSRS questionnaires completed at the end of the study showed that there was no 
difference in the global mean gastrointestinal health score from the Tritordeum diet and the 
Basal (gluten-free bread) diet. Also, at the individual level there were no significant differences 
in gastro-intestinal health scores from the two diet phases. Thus, over the seven-day 
intervention period at the level of tritordeum bread consumed (100 – 150 g daily, from four 
slices of bread) all the NCWS patients showed good tolerance, with no deterioration in gastro-
intestinal wellbeing, comparable to that of the gluten free bread of their choice. 
The measurement of GIP levels in stool samples after each of the two phases of the 
study showed that, as expected, during the Basal phase subjects had lower GIP excretion, but 
that GIP excretion was observed during the Tritordeum phase, confirming the consumption of 
gluten. The levels of GIP detected in stool samples from the Tritordeum phase (mean 1.5 µg 
GIP/g feces) were similar to the levels detected in the previous study using healthy subjects, 
which had a mean of 1.2 and a range of 0.16 to 14.87 µg GIP/g feces and in which the subjects 
consumed the same quantity of tritordeum bread daily (21). However, two individuals showed 
high levels of GIP (2.5 and 2.9 µg GIP/g feces) excretion during the Basal (gluten-free bread) 
 
 
phase, indicating gluten exposure (volunteer or not) of the GFD. Values of GIP excretion for 
these two individuals in the Tritordeum phase were 1.1 and 1.9 µg GIP/g feces, respectively. 
Considering the evaluation of acceptance of tritordeum bread in comparison with the 
gluten-free breads habitually consumed by the subjects, the Sensory Questionnaire showed 
that tritordeum breads were given significantly higher scores for all five of the acceptance 
attributes. Taste and texture in tritordeum bread were rated particularly highly in comparison 
with gluten-free breads and the subjects had a clear overall preference for tritordeum breads, 
awarding a mean Global Acceptance score of 7.2 for tritordeum versus 5.1 for gluten-free 
breads. 
There is considerable controversy surrounding NCWS, because unlike the other gluten-
related disorders CD and WA whose diagnosis is based on objective parameters, supported by 
accepted biomarkers, the diagnosis of NCWS is based on the presence of intestinal and extra-
intestinal symptoms associated with the consumption gluten-containing foods and on negative 
results for CD and WA biomarkers (24). At the pragmatic level, NCWS sufferers are diagnosed 
by the exclusion of CD and WA and by the disappearance of symptoms on the adoption of a 
GFD (34). Further, there is active discussion as to whether NCWS is a disease separate from 
irritable bowel syndrome (IBS), as several studies suggest that the symptoms overlap and that 
FODMAPS may play a major role in addition to / rather than gluten (4, 35), although other 
studies present evidence that gluten-induced reactions are responsible for NCWS symptoms 
(36, 37) and ATIs also may play a role (4). Some studies suggest that ATIs could trigger the 
innate immune response in the intestinal monocytes, macrophages and dendritic cells, leading 
to the release of pro-inflammatory cytokines, providing intestinal inflammation (38, 39). In 
addition, it has been shown that FODMAPs, particularly fructans, could be the main trigger of 
NCWS in certain patients (40) , as 24 out of 59 participants in the study had the highest 
Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) scores after 
 
 
consuming fructan. However, 22 out of 59 participants had the highest score after consuming 
placebo. The mechanism of fructans, or other FODMAPS, in inducing NCWS is not clear. 
FODMAPs are not digested nor absorbed in the gastrointestinal tract and their rapid 
fermentation in the intestines, may result in excessive gas production, bloating and pain. 
Tritordeum contains fructans at comparable levels of bread wheat. In this work, compounds 
like ATIs or fructans were not analyzed in all the different gluten-free breads consumed by the 
NCWS participant. However, the fructan content has been determined in a wide range of 
wheat, rye and gluten-free breads (41). Surprisingly, the fructan content in gluten-free breads 
was very similar to that of gluten-containing breads. This is possibly due to the enrichment of 
gluten-free breads with Inulin-type fructans (ITFs) to improve the nutritional quality of gluten-
free breads (42). In fact, Morreale et al. (43) reported the fructan content of gluten-free 
breads enriched with various types of ITFs and show that fructan concentrations were up to 
4.59 g / 100 g (wet basis) in some gluten-free breads.  
While the exact causal mechanism for NCWS has still to be defined, it appears evident 
that there exist a very significant number of people who report symptoms when they consume 
wheat-containing foods, with frequencies estimated between 6 and 13% in different 
populations (44). These figures are related to a strong increase in the avoidance of wheat and 
other gluten-containing cereals over the last decade, with estimates up to 10 – 20% of 
populations in Westernized countries (4). The avoidance of wheat has resulted in an almost 
exponential increase in the adoption of GFDs (44), although there is increasing recognition that 
at the nutritional level GFDs tend to be inferior to cereal-containing diets due to increased 
levels of fats, and reduced levels of complex carbohydrate, protein, vitamins and minerals (8, 
44). In addition, there is overwhelming evidence for the positive effects of the consumption of 
dietary fiber as supplied by wholegrain cereals, and it is more difficult to consume the 
recommended levels of dietary fibre when observing a GFD (45, 46).  
 
 
In contrast to CD, there is evidence that some NCWS sufferers may not need to totally 
exclude cereals from their diets, but may be able to tolerate a reduced gluten intake or gluten 
sources with reduced levels of GIP, either from the use of alternative cereal flours or by gluten 
modification via processes such as sourdough fermentation (9, 19). This concept is supported 
by the results of the present study, in which a group of ten medically-diagnosed NCWS 
sufferers who follow a GFD and habitually consume gluten-free bread were able to consume 
100 – 150g of tritordeum bread daily, giving an estimated daily gluten consumption of 5 – 7.5 g 
over a period of seven days, without any of them reporting a change in gastro-intestinal health 
parameters. 
Finally, evidence is emerging that GFDs may negatively affect the gut microbiota (10-
12). In this sense, our study has not observed global changes in the diversity of the intestinal 
microbiota between the Basal phase and the Tritordeum phase. However, we have found a 
significant decrease in the relative abundance of Ruminococcaceae UCG-013 gnus and a 
significant increase of Faecalibacterium genus after consumption of tritordeum bread. Both 
genera belong to the Ruminococcaceae , a bacterial family that is associated with intestinal 
health maintenance (47) .  
One interesting results was the observed increase in the relative abundance of 
Faecalibacterium genus after seven days of consumption of tritordeum bread. 
Faecalibacterium is one well-known butyrate producing bacteria within the human intestinal 
gut microbiota (48). A new pathogenic mechanism involved in NCWS has recently been 
proposed in which butyrate producing bacteria, especially Faecalibacterium among others may 
play a key beneficial role NCGS (15, 49-51). Butyrate constitutes the energy source of the 
enterocytes, keep the tight junctions, stimulates mucin production avoiding intestinal 
permeability, and finally it induces the production of antimicrobial peptides (52, 53). Taken 
together, all these functions of butyrate ultimately result in intestinal homeostasis and 
 
 
immune tolerance (48, 54). In line with this, our results may suggest that the long-term 
consumption of tritordeum could be a good alternative to GFD in patients with NCWS, if the 
increase on Faecalibacterium abundance observed after one week of tritordeum bread intake 
is maintained at long term.  
In addition, according to the PLS-DA analysis, the microbial community of both phases 
tends to separate associated to differences of important SCFA-producing bacteria. Thus, we 
have observed that after the consumption of the tritordeum bread, besides Faecalibacterium 
genus, that increases its relative abundance significantly, other SCFA-producing bacteria show 
a similar trend including [Ruminococcus] gauvreauii group (55), Roseburia (47-49), Clostridium 
sensu stricto 1  (56), Bacteroides (57), Lachnoclostridium, [Eubacterium] xylanophilyum group 
(58), and Lachnospiraceae NK4A136 group (59) (Fig. 6). This data is relevant since the SCFA are 
involvement in the preservation of the integrity of the intestinal barrier (18). To confirm those 
trends, future studies are needed increasing the number of patients included in the study as 
well as increasing the period of consumption of tritordeum bread to confirm its long-term 
positive effects on the intestinal microbiota by increasing SCFA producing bacteria 
demonstrating the increase of these metabolites after its consumption. 
CONCLUSIONS 
The present study shows that a group of ten diagnosed NCWS subjects who follow a 
GFD were able to consume tritordeum breads for a week without suffering negative effects on 
gastro-intestinal health. In terms of acceptability, participating subjects showed clear 
preference for tritordeum breads in comparison with their usual GF bread. Tritordeum bread 
intake show significantly reduced levels of GIP excretion by comparison with standard wheat 
bread as reported in a previous study of the group, although it cannot be concluded from the 
present study that this is the only factor which may have allowed its tolerance by NCWS 
subjects. Nevertheless, the results suggest that tritordeum may be tolerated by some of NCWS 
 
 
sufferers who do not require strict exclusion of gluten from their diet and may benefit from its 
better organoleptic and nutritional properties. In addition, although the global structure and 
composition of the intestinal microbiota of each patient was stable after tritordeum bread 
consumption, there was a trend to increase the relative abundance of some SCFA-producing 
bacteria, which may suggest a potential increase of the intestinal healthy status in these 
patients. 
ACKNOWLEDGEMENTS 
This research was funded by The Spanish Ministry of Economy and Competitiveness, 
Project AGL2016-80566-P and the European Regional Development Fund (FEDER). The 
technical assistance of Ana García is acknowledged. We thank Dr. Paul Lazzeri for his review of 
the manuscript. We also thank the generous volunteer subjects who enrolled in the study. 
REFERENCES 
 
1. Shewry PR, Hey SJ. The contribution of wheat to human diet and health. Food 
Energy Secur. 2015;4(3):178-202. 
2. Tatham AS, Shewry PR. Allergens to wheat and related cereals. Clin Exp 
Allergy. 2008;38(11):1712-26. 
3. Lebwohl B, Ludvigsson JF, Green PHR. Celiac disease and non-celiac gluten 
sensitivity. BMJ. 2015;351:h4347. 
4. Dale HF, Biesiekierski JR, Lied GA. Non-coeliac gluten sensitivity and the 
spectrum of gluten-related disorders: an updated overview. Nutr Res Rev. 
2019;32(1):28-37. 
5. Aziz I, Dwivedi K, Sanders DS. From coeliac disease to noncoeliac gluten 
sensitivity; should everyone be gluten free? Curr Opin Gastroenterol. 2016;32(2):120-7. 
6. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PHR, Hadjivassiliou M, et al. 
Spectrum of gluten-related disorders: consensus on new nomenclature and 
classification. BMC Med. 2012;10(1):13. 
7. Roncoroni L, Bascuñán KA, Vecchi M, Doneda L, Bardella MT, Lombardo V, et 
al. Exposure to Different Amounts of Dietary Gluten in Patients with Non-Celiac Gluten 
Sensitivity (NCGS): An Exploratory Study. Nutrients. 2019;11(1):136. 
8. Larretxi I, Simon E, Benjumea L, Miranda J, Bustamante MA, Lasa A, et al. 
Gluten-free-rendered products contribute to imbalanced diets in children and 
adolescents with celiac disease. Eur J Nutr. 2019;58(2):775-83. 
9. Gobbetti M, Pontonio E, Filannino P, Rizzello CG, De Angelis M, Di Cagno R. 
How to improve the gluten-free diet: The state of the art from a food science 
perspective. Food Res Int. 2018;110:22-32. 
 
 
10. De Palma G, Nadal I, Collado MC, Sanz Y. Effects of a gluten-free diet on gut 
microbiota and immune function in healthy adult human subjects. Br J Nutr. 
2009;102(8):1154-60. 
11. Lorenzo Pisarello MJ, Vintiñi EO, González SN, Pagani F, Medina MS. 
Decrease in lactobacilli in the intestinal microbiota of celiac children with a gluten-free 
diet, and selection of potentially probiotic strains. Can J Microbiol. 2015;61(1):32-7. 
12. Haro C, Villatoro M, Vaquero L, Pastor J, Giménez MJ, Ozuna CV, et al. The 
Dietary Intervention of Transgenic Low-Gliadin Wheat Bread in Patients with Non-
Celiac Gluten Sensitivity (NCGS) Showed No Differences with Gluten Free Diet (GFD) 
but Provides Better Gut Microbiota Profile. Nutrients. 2018;10(12):1964. 
13. Daulatzai MA. Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, 
Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia. CNS 
Neurol Disord Drug Targets. 2015;14(1):110-31. 
14. Volta U, Caio G, Karunaratne TB, Alaedini A, De Giorgio R. Non-coeliac 
gluten/wheat sensitivity: advances in knowledge and relevant questions. Expert Rev 
Gastroent. 2017;11(1):9-18. 
15. Uhde M, Ajamian M, Caio G, De Giorgio R, Indart A, Green PH, et al. Intestinal 
cell damage and systemic immune activation in individuals reporting sensitivity to 
wheat in the absence of coeliac disease. Gut. 2016;65(12):1930-7. 
16. Hansen LBS, Roager HM, Søndertoft NB, Gøbel RJ, Kristensen M, Vallès-
Colomer M, et al. A low-gluten diet induces changes in the intestinal microbiome of 
healthy Danish adults. Nat Commun. 2018;9(1):4630. 
17. Caminero A, Verdu EF. Metabolism of wheat proteins by intestinal microbes: 
Implications for wheat related disorders. Gastroenterol Hepatol. 2019;42(7):449-57. 
18. Brenchley JM, Douek DC. Microbial Translocation Across the GI Tract. Annu 
Rev Immunol. 2012;30(1):149-73. 
19. Calasso M, Francavilla R, Cristofori F, De Angelis M, Gobbetti M. New Protocol 
for Production of Reduced-Gluten Wheat Bread and Pasta and Clinical Effect in 
Patients with Irritable Bowel Syndrome: A randomised, Double-Blind, Cross-Over 
Study. Nutrients. 2018;10(12):1873. 
20. Muir JG, Varney JE, Ajamian M, Gibson PR. Gluten-free and low-FODMAP 
sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical 
perspective. Int J Food Microbiol. 2019;290:237-46. 
21. Vaquero L, Comino I, Vivas S, Rodríguez-Martín L, Giménez MJ, Pastor J, et al. 
Tritordeum: a novel cereal for food processing with good acceptability and significant 
reduction in gluten immunogenic peptides in comparison with wheat. J Sci Food Agric. 
2018;98(6):2201-9. 
22. Cubero JI, Martin A, Millán T, Gómez-Cabrera A, de Haro A. Tritordeum: A New 
Alloploid of Potential Importance as a Protein Source Crop1. Crop Sci. 
1986;26(6):1186-90. 
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Figure 1. Participants recruitment and dietary intervention flow. 
Figure 2. Comparison of the Symptom Rating Scale (GSRS) questionnaire for all patients 




Figure 3. Comparison of the fecal Gluten Immunogenic Peptides (GIP) content after 
consumption of gluten-free bread (basal) and tritordeum breads. 
 
Figure 4. Differences in descriptive sensory analysis of the two phases of the dietary 
intervention. Values of the sensory questionnaire for Overall acceptance, Appearance, Aroma, 
Texture, and Taste of the sensory questionnaire for the gluten-free bread (basal) and 
tritordeum bread. Data are the means of ten replications +/- standard deviation. 
 
Figure 5. Alpha and Beta diversity analysis results. (A) Alpha rarefaction curves of Faith_pd, 
Shannon and Observed otus alpha diversity indexes for the Basal and Tritordeum phase at a 
depth of 10044 sequences per sample. P-value for each alpha diversity index was estimated 
using Kruskal-Wallis test. (B) Principal Coordinate Analysis (PCoA) of the unweighted and 
weighted UniFrac beta diversity distances between the Basal and Tritordeum phase at a depth 
of 10044 sequences per sample. P-value was estimated using a Permanova test comparing the 
Basal and Tritordeum phases globally or for each patient independently. 
 
Figure 6. Partial Least Squares - Discriminant Analysis (PLS-DA). (A) Partial least square-
discriminant analysis (PLS-DA) 2D scores plot of the bacterial taxa of each phase of study. Red: 
Basal phase; Green: Tritordeum phase. The model was established using two principal 
components; explained variance is in parentheses. (B) Loading importance of bacterial taxa in 
the first PLS-DA component. Colored boxes (red: Basal phase; green: Tritordeum phase) 
indicate relative concentrations of the corresponding bacterial taxa in each phase. VIP: 




Figure 7. Summary taxa of Basal and Tritordeum phases at genus level.  Graphs represented 
show the bar plots with the relative abundance of each taxonomic group in percentage within 
each phase, Basal and Tritordeum at genus level. Other corresponds to the sum of unassigned 
taxa with the Silva 132 database and the bacterial taxa present in less 80% of the samples per 
each phase. Colored asterisks show significantly different taxa with P-value < 0.05. The 
statistically significant differences between each phase were tested by non-parametric Mann–
Whitney U test. 
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